CA2758847A1 - Bioavailable capsule compositions of amorphous alpha-(n-sulfonamido)acetamide compound - Google Patents

Bioavailable capsule compositions of amorphous alpha-(n-sulfonamido)acetamide compound Download PDF

Info

Publication number
CA2758847A1
CA2758847A1 CA2758847A CA2758847A CA2758847A1 CA 2758847 A1 CA2758847 A1 CA 2758847A1 CA 2758847 A CA2758847 A CA 2758847A CA 2758847 A CA2758847 A CA 2758847A CA 2758847 A1 CA2758847 A1 CA 2758847A1
Authority
CA
Canada
Prior art keywords
capsule
peg
tpgs
pharmaceutical composition
crystallization inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2758847A
Other languages
English (en)
French (fr)
Inventor
Sachin Chandran
Rajesh Babulal Gandhi
Jaquan Kalani Levons
Robert Kevin Perrone
Christopher P. Price
Krishnaswamy Srinivas Raghavan
Ismat Ullah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CA2758847A1 publication Critical patent/CA2758847A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2758847A 2009-04-14 2010-04-13 Bioavailable capsule compositions of amorphous alpha-(n-sulfonamido)acetamide compound Abandoned CA2758847A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16906109P 2009-04-14 2009-04-14
US61/169,061 2009-04-14
PCT/US2010/030862 WO2010120755A1 (en) 2009-04-14 2010-04-13 Bioavailable capsule compositions of amorphous alpha-(n-sulfonamido)acetamide compound

Publications (1)

Publication Number Publication Date
CA2758847A1 true CA2758847A1 (en) 2010-10-21

Family

ID=42235859

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2758847A Abandoned CA2758847A1 (en) 2009-04-14 2010-04-13 Bioavailable capsule compositions of amorphous alpha-(n-sulfonamido)acetamide compound

Country Status (14)

Country Link
US (1) US8252821B2 (https=)
EP (1) EP2419090B1 (https=)
JP (1) JP2012524092A (https=)
KR (1) KR20120022766A (https=)
CN (1) CN102395361A (https=)
AR (1) AR076305A1 (https=)
AU (1) AU2010236602A1 (https=)
BR (1) BRPI1015483A2 (https=)
CA (1) CA2758847A1 (https=)
EA (1) EA201101286A1 (https=)
MX (1) MX2011010514A (https=)
NZ (1) NZ595335A (https=)
TW (1) TW201041609A (https=)
WO (1) WO2010120755A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2471099C (en) 2001-12-20 2011-04-12 Bristol-Myers Squibb Company .alpha.-(n-sulphonamido)acetamide derivatives as .beta.-amyloid inhibitors
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
WO2011040797A2 (ko) 2009-10-02 2011-04-07 엘지전자 주식회사 하향링크 참조신호의 전송방법 및 장치
ES2565353T3 (es) 2010-12-16 2016-04-04 Borje S. Andersson Formulaciones farmacéuticas de azol para administración parenteral y métodos para la preparación y el uso de las mismas como tratamiento de enfermedades sensibles a los compuestos de azol
DK2701684T3 (en) 2011-04-28 2017-09-18 Platform Brightworks Two Ltd Improved parenteral formulations of lipophilic pharmaceuticals and methods for their preparation and use
US20130302414A1 (en) * 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
US20220175760A1 (en) * 2019-02-22 2022-06-09 Janssen Pharmaceutica Nv Pharmaceutical formulations
EP3953345B1 (en) 2019-04-11 2023-04-05 Janssen Pharmaceutica NV Pyridine rings containing derivatives as malt1 inhibitors
JP2023538099A (ja) * 2020-08-21 2023-09-06 ヤンセン ファーマシューティカ エヌ．ベー． Ｍａｌｔ１阻害剤と、ポリエチレングリコールの脂肪酸との混合物と、を含む、医薬製剤

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274094A (en) 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) 1992-02-11 1992-03-25 British Bio Technology Compounds
SK282833B6 (sk) 1995-11-17 2002-12-03 Warner-Lambert Company Sulfónamidové inhibítory matricových metaloproteináz a farmaceutická kompozícia obsahujúca tieto inhibítory
JP2000515153A (ja) 1996-07-22 2000-11-14 モンサント カンパニー チオールスルホンアミド メタロプロテアーゼインヒビター
JP2001523221A (ja) * 1996-09-01 2001-11-20 ファーモス コーポレイション 親油性物質の促進された生物学的利用能のための固形共沈物
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
AU766192B2 (en) 1999-01-27 2003-10-09 Wyeth Holdings Corporation Acetylenic sulfonamide thiol tace inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
NZ514453A (en) 1999-02-26 2003-04-29 Merck & Co Inc Novel sulfonamide compounds and uses thereof
IL160761A0 (en) * 2001-10-19 2004-08-31 Isotechnika Inc Novel cyclosporin analog microemulsion preconcentrates
CA2471099C (en) 2001-12-20 2011-04-12 Bristol-Myers Squibb Company .alpha.-(n-sulphonamido)acetamide derivatives as .beta.-amyloid inhibitors
KR20060002908A (ko) 2003-03-31 2006-01-09 와이어쓰 베타 아밀로이드 생산 억제제인 플루오로- 및트리플루오로알킬-함유 헤테로사이클릭 설폰아미드 및 이의유도체
CA2544350A1 (en) 2003-10-29 2005-05-12 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
US7163942B2 (en) 2004-04-01 2007-01-16 Pfizer Inc. Sulfonamide compounds for the treatment of neurodegenerative disorders
CA2595116A1 (en) * 2004-04-28 2005-11-10 Procarrier, Inc. Oral formulation for delivery of poorly absorbed drugs
EP1768960A1 (en) 2004-07-13 2007-04-04 F.Hoffmann-La Roche Ag Sulfonamide derivatives
US7144894B2 (en) 2004-09-23 2006-12-05 Bristol-Myers Squibb Company Sulfonamide bicyclic compounds
WO2006065710A1 (en) * 2004-12-14 2006-06-22 Wyeth Use of a 5-ht6 agonist for the treatment and prevention of neurodegenerative disorders
AR059517A1 (es) 2006-02-17 2008-04-09 Wyeth Corp N- sulfonilacion selectiva de alcoholes sustituidos con 2- aminotrifluoralquilo
EP1984321A1 (en) 2006-02-17 2008-10-29 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
WO2007103683A2 (en) * 2006-03-01 2007-09-13 Roskamp Research Llc Compounds for inhibiting beta-amyloid production
WO2008112249A1 (en) 2007-03-13 2008-09-18 Trustees Of Columbia University In The City Of New York Synergistic interaction of notch-1 inhibitors with glucocorticoids
WO2009005688A2 (en) 2007-06-29 2009-01-08 Trustees Of Columbia University In The City Of New York Activating mutations in notch-1
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
WO2009137657A1 (en) 2008-05-08 2009-11-12 Bristol-Myers Squibb Company 2-aryl glycinamide derivatives
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
CN102438622A (zh) 2009-03-19 2012-05-02 百时美施贵宝公司 作为β淀粉样肽产生抑制剂的新颖α-(N-磺酰氨基)乙酰胺化合物
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US20110071199A1 (en) 2009-03-20 2011-03-24 Bristol-Myers Squibb Company Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease
TW201043269A (en) 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound

Also Published As

Publication number Publication date
MX2011010514A (es) 2011-11-29
CN102395361A (zh) 2012-03-28
JP2012524092A (ja) 2012-10-11
EP2419090A1 (en) 2012-02-22
KR20120022766A (ko) 2012-03-12
TW201041609A (en) 2010-12-01
BRPI1015483A2 (pt) 2016-04-26
AR076305A1 (es) 2011-06-01
EA201101286A1 (ru) 2012-04-30
US8252821B2 (en) 2012-08-28
AU2010236602A1 (en) 2011-10-13
US20100260837A1 (en) 2010-10-14
EP2419090B1 (en) 2013-02-13
WO2010120755A1 (en) 2010-10-21
NZ595335A (en) 2013-03-28

Similar Documents

Publication Publication Date Title
US8252821B2 (en) Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
AU2011273519B2 (en) Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl) -1H-benzimidazol-2-yl]-1H-quinolin-2-one lactate monohydrate
ES2641637T3 (es) Composiciones farmacéuticas que comprenden ligandos del receptor sigma
ES2935792T3 (es) Formas farmacéuticas orales de bendamustina y uso terapéutico de las mismas
PL209704B1 (pl) Kompozycja farmaceutyczna w postaci tabletki do sporządzania zawiesin oraz sposób wytwarzania tabletki do sporządzania zawiesin zawierającej 40-O-(2-hydroksy)etylo-rapamycynę
JPWO2008129846A1 (ja) 医薬組成物
CN101636152A (zh) 含有西洛他唑的控释制剂及其制备方法
JP5749247B2 (ja) 経口用徐放性固形製剤
CN110292575B (zh) 药物组合物
JP2011500548A (ja) マンニトールおよび／または微結晶性セルロースを含むジボテンタン組成物
JPWO2010147169A1 (ja) 溶出性の改善された医薬組成物
EP2419086B1 (en) Bioavailable compositions of amorphous alpha-(n-sulfonamido)acetamide compound
JP6093762B2 (ja) 徐放性製剤
ES2437916T3 (es) Composición de raloxifeno
US20260069569A1 (en) Ebselen containing oral dosage forms
US20250352482A1 (en) Amorphous dosage form containing ebselen
WO2024043842A1 (en) Pharmaceutical compositions comprising chenodeoxycholic acid (cdca) as active ingredient and other relevant excipients

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160413